Welcome to the Working Group on New TB Drugs Blog
Tagline Spring 2013: 3 Articles on TB Research
Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access, 2) on adaptive clinical trial designs, and 3) on pediatric drug development needs.
Bedaquiline Receives Accelerated Approval from the FDA for MDR-TB Rx
The FDA granted Janssen’s TB drug Bedaquiline accelerated approval for treatment of MDR-TB. A link is provided to the FDA press release and Janssen’s full press release is included.
Posted in Announcements, market access, TB News, TB Prevention and Control Strategies, TB Treatment, Video
Private TB Drug Market is Larger than Expected
The first detailed study of the private tuberculosis (TB) drug market, published on May 4th, in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-TB).
WHO Endorses New Rapid Diagnostic Test for TB
Yesterday, Mario Raviglione , Director of Stop TB, and Giorgio Roscigno, CEO of FIND, held a global press conference announcing the World Health Organization’s endorsement of the new rapid diagnostic test Xpert MTB/RIF. If implemented to scale in countries where tuberculosis (TB) is endemic, it could revolutionize how TB is diagnosed and treated. The test could have a significant impact on patients that are smear negative, HIV positive, or infected with drug-resistant TB.
GlaxoSmithKline Finds Compound That Could Help Fight ‘Superbugs’
GlaxoSmithKline (GSK) researchers announced Wednesday that they have found a new compound that may help in the fight against drug-resistant bacteria. The findings could ultimately assist scientists in developing new antibiotics to tackle what has been called one of the world’s most pressing public health problems. Last year, a report from the American Academy of Microbiology called antibiotic resistance “an international pandemic,” adding that “resistance essentially is uncontrollable.”
This week in TB R&D – 20 April 2010
Despite the massive need for new TB drugs, the commercial viability of the TB drug market has long been viewed as questionable at best. Reports suggest that there is a substantial market that will grow year-over-year, though there is no firm conclusion about its commercial viability. The first widely-circulated analysis was done by the Global [...]
-
Toppix TB News- TB, a neglected disease in Uganda 15 May 2013
- Dr. John: Medications, T.B, tinnitus 8 May 2013
- U.S. non-profit group to build tuberculosis center in Pyongyang 4 May 2013
- Predictors of tuberculosis (TB) and antiretroviral (ARV) medication... 26 Apr 2013
- Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr.... 26 Apr 2013
